Definium Therapeutics Inc. Common Shares (DFTX)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Definium Therapeutics with Graham's caution and Buffett's preference for understandable, cash-generating businesses. This is a clinical-stage biopharmaceutical company with 105 employees and no reported revenue in the filed periods. Its lead candidates, DT120 in Phase 3 and DT402 in Phase 2a, address brain-health disorders; that is promising science, but the filed numbers show a business still consuming capital. In fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$159.0M and diluted EPS -$1.44. In fiscal Q1 2026, the quarter ended 2026-03-31, net income was -$77.1M and diluted EPS -$0.71. For FY2025, net income was -$183.8M and diluted EPS -$2.06; FY2024 was -$108.7M and FY2023 was -$95.7M. Losses are widening, and trailing free cash flow is -$168.0M, a -3.6% FCF yield as a FairStock calculation. The Piotroski F-score is 2/9, ROE is -64.09%, and ROCE is -20.64%, also FairStock calculations. A positive is low debt: D/E is 0.04, and the Altman Z-score is 14.25, suggesting the capital structure is not leveraged. The market cap is $4.6B at the 2026-10-13 close of $34.38, while P/B is 5.03 and P/E is -10.02; those are FairStock calculations and reflect no earnings. The FairStock Score is 23/100 and the Lynch category is none because it has lost money each of the last four years. The moat, if any, is unproven and depends on clinical and regulatory outcomes. I see a speculative, binary pipeline, not a value investment with a margin of safety.

In plain English: Definium Therapeutics is a clinical-stage biotech company with no product revenue, developing brain-health drugs for anxiety, depression and autism. It loses money every year and burns cash, so the business looks financially weak and unproven. At $34.38 on 2026-10-13, the $4.6 billion market value depends mostly on future trial success, not on current profits, so the price looks speculative rather than cheap on today's numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer